Continuous glucose monitors (CGMs) are rapidly becoming an important tool for improving glycemic outcomes in diabetes. CGMs can potentially be used by hospitalized patients to sound alarms for impending hypoglycemia, inform insulin dosing, and provide an indicator of stress or well-being. Since the beginning of the COVID-19 pandemic in 2020, the FDA provided a policy to help expand the availability and capability of CGMs to facilitate patient monitoring while reducing patient and healthcare provider exposure to COVID-19. Interest in utilizing CGMs in the hospital has been stimulated by four trends in the application of CGM technology, including (1) improvements in the technology and human factors of CGMs, (2) an increasing number of patients wearing CGMs in ambulatory settings, (3) growing interest by clinicians to understand and interpret the glucose concentrations of hospitalized patients, and (4) an accumulation of published reports describing the use of these products in investigational settings. Diabetes Technology Society (DTS) organized the Continuous Glucose Monitor and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel, which met virtually on April 23, 2020. The panelists voted for a consensus guideline containing 77 recommendations intended to support management of hospitalized patients with diabetes. Since then, many hospital clinicians have gained experience using CGMs for research studies or clinical care. DTS is now planning a virtual Hospital Diabetes Meeting for April 14-15, 2023 to review progress in the field of using CGMs in the hospital. This meeting will cover barriers and solutions to the use of this tool in various hospital settings as well as results of research abstracts. At this event, an international faculty of experts in the use of CGMs in the hospital will share their experiences, recommendations, and future plans.
David C. Klonoff, MD, FACP, FRCPE, Fellow AIMBE
President, Diabetes Technology Society